We can’t show the full text here under this license.
Abstract
Type 2 diabetes mellitus (T2D) is closely associated with metabolic dysfunction-associated steatotic liver disease (MASLD), which has a high prevalence in T2D patients.
- There is a bidirectional relationship between T2D and MASLD, driven by insulin resistance, chronic inflammation, and increased lipid deposition.
- MASLD is a leading cause of cirrhosis and hepatocellular carcinoma (HCC).
- Management of T2D in patients with MASLD includes lifestyle interventions and optimization of cardiometabolic risk factors.
- Antidiabetic medications, such as SGLT-2 inhibitors and GLP-1 receptor agonists, may be evaluated for their role in treatment.
- Early identification of MASLD could help guide treatment strategies and reduce progression to liver cirrhosis in high-risk individuals.
Simplified